Kelun-Biotech, Harbour BioMed Secure NMPA Approval for Atopic Dermatitis Candidate
Event summary
- Kelun-Biotech and Harbour BioMed received NMPA approval for an IND application for SKB575/HBM7575, a bispecific antibody targeting TSLP and an undisclosed antigen.
- The candidate is designed for the treatment of atopic dermatitis, a condition affecting approximately 20% of children and 10% of adults globally.
- SKB575/HBM7575 is expected to have a long-acting profile, potentially enabling dosing intervals of over three months.
- Kelun-Biotech leads the design, global development, and commercialization of the asset, with Harbour BioMed participating in investment and development.
The big picture
The approval represents a strategic move by Kelun-Biotech to expand its presence in the autoimmune disease space, leveraging Harbour BioMed’s antibody technology platform. The long-acting profile of SKB575/HBM7575 addresses a key unmet need in atopic dermatitis treatment – sustained disease control with reduced dosing frequency – potentially offering a competitive advantage. The undisclosed target adds an element of strategic opacity, suggesting a novel mechanism designed to overcome resistance seen with TSLP-targeting therapies alone.
What we're watching
- Clinical Efficacy
- The success of SKB575/HBM7575 will hinge on demonstrating superior efficacy and safety compared to existing treatments in clinical trials, particularly given the prevalence of JAK inhibitors and topical corticosteroids.
- Undisclosed Target
- The undisclosed target's identity and mechanism of action will be critical to understanding the drug's overall effectiveness and potential for synergistic effects with TSLP blockade.
- Commercialization
- Kelun-Biotech’s ability to effectively commercialize the drug in China and potentially globally will depend on navigating the NMPA approval process and establishing a robust distribution network.
Related topics